Recombinant Human FAP His-tag (Mammalian) Protein, CF
Recombinant Human FAP His-tag (Mammalian) Protein, CF Summary
Product Specifications
Leu26-Asp760 with an N-terminal 6-His tag
Analysis
Product Datasheets
10921-SE
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
10921-SE
| Formulation | Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 50 mM Tris, 1 M NaCl, 1 mg/mL BSA, pH 7.5
- Recombinant Human FAP (rhFAP) (Catalog # 10921-SE)
- Substrate: Z-Gly-Pro-AMC (Bachem, Catalog # I-1145), 10 mM stock in DMSO
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Fluorescent Plate Reader (Model: SpectraMax M5 by Molecular Devices) or equivalent
- Dilute rhFAP to 0.2 µg/mL in Assay Buffer.
- Dilute Substrate to 200 µM in Assay Buffer.
- Load in a plate 50 µL of 0.2 µg/mL of rhFAP, and start the reaction by adding 50 µL of 200 µM Substrate. Include a Substrate Blank containing 50 µL of Assay Buffer and 50 µL of Substrate.
- Read at excitation and emission wavelengths of 380 nm and 460 nM (top read), respectively, in kinetic mode for 5 minutes.
- Calculate specific activity:
Specific Activity (pmol/min/µg) = | Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU) |
| amount of enzyme (µg) |
*Adjusted Substrate Blank
**Derived using calibration standard 7-Amino, 4-Methyl Coumarin (Sigma, Catalog # A-9891).
- rhFAP: 0.01 µg
- Substrate: 100 µM
Scientific Data
View Larger
Recombinant Human FAP His-tag (Mammalian) (Catalog # 10921-SE) has a molecular weight (MW) of 194.0 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).
View Larger
Recombinant Human FAP His-tag (Mammalian) (Catalog # 10921-SE) is measured by its ability to convert the substrate benzyloxycarbonyl-Gly-Pro-7-amido-4-methylcoumarin (Z-GP-AMC) to Z-Gly-Pro and 7-amino-4-methylcoumarin (AMC).
View Larger
2 μg/lane of Recombinant Human FAP His-tag Protein (Catalog # 10921-SE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 83-92 kDa.
Background: Fibroblast Activation Protein alpha/FAP
FAP (also known as seprase) is a 95 kDa Type II transmembrane serine protease that forms a homodimer and is structurally related to the dipeptidyl peptidase IV (DPPIV/CD26) family with a short cytoplasmic tail, a single transmembrane domain, and an extracellular domain that contains the active site (1-3). It exhibits dipeptidyl peptidase activity with substrate specificity similar to DPPIV, which is specific for N-terminal Xaa-Pro sequences (4,5). FAP is also an endopeptidase that can degrade Gelatin, Collagens I and IV, Fibronectin, and Laminin (1,4,5) as well as several peptide hormones (e.g. Neuropeptide Y, Brain Natriuretic Peptide, Substance P, Peptide YY, and Incretins) (6). FAP is also known to interact with several surface molecules to play roles in cell signaling, cell invasion and migration (3). Although not detectible in normal tissues, FAP is elevated in activated stromal fibroblasts, tumor-associated macrophages, activated hepatic stellate cells and myofibroblasts during pathological conditions that include tissue remodeling such as most types of cancer, wound healing, arthritis, atherosclerosis, and fibrosis (1,3,4,7-9). Targeting FAP with vaccines, antibodies, or pharmacologics impairs tumor progression in several cancer models making it a promising immunotherapy target (9-12).
- Zi, F. et al. (2015) Mol. Med. Rep. 11:3203.
- Pineiro-Sanchez, M.L. et al. (1997) J. Biol. Chem. 272:7595.
- Lay, A.J. et al. (2019) Front Biosci. 24:1.
- Park, J.E. et al. (1999) J. Biol. Chem. 274:36505.
- Aertgeerts, K. et al. (2005) J. Biol. Chem. 280:19441.
- Keane, F.M. et al. (2011) FEBS J. 278:1316.
- Rettig, W.J. et al. (1988) Proc. Natl. Acad. Sci. USA 85:3110.
- Bauer, S. et al. (2006) Arthritis Res. 8:R171.
- Jiang, G.M. et al. (2016) Oncotarget 7:33472.
- Cheng, J.D. et al. (2002) Cancer Res. 62:4767.
- Kraman, M. et al. (2010) Science 330:827.
- Busek, P. et al. (2018) Front. Biosci. 23:1933.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human FAP His-tag (Mammalian) Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human FAP His-tag (Mammalian) Protein, CF and earn rewards!
Have you used Recombinant Human FAP His-tag (Mammalian) Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
